keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/29145737/pembrolizumab-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer
#1
Martin Reck
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between programmed death-1 and programmed death-ligand 1 and 2 [PD-L1/PD-L2]) as first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the Phase III KEYNOTE-024 study, pembrolizumab monotherapy significantly improved progression-free survival (primary end point) and overall survival, and was associated with fewer adverse events compared with platinum-based chemotherapy in patients with NSCLC with PD-L1 expression on ≥50% of tumor cells...
November 17, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29135283/10th-annual-symposium-on-self-monitoring-of-blood-glucose-april-27-29-2017-warsaw-poland
#2
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Warsaw, Poland, for the 10th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts to facilitate new collaborations and research projects that can improve the lives of people with diabetes. The 2017 meeting comprised a comprehensive scientific program, parallel interactive workshops, and four keynote lectures.
November 14, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29133982/combined-aesthetic-interventions-for-prevention-of-facial-ageing-and-restoration-and-beautification-of-face-and-body
#3
Sabrina Fabi, Tatjana Pavicic, André Braz, Jeremy B Green, Kyle Seo, Jani Aj van Loghem
The Merz Institute of Advanced Aesthetics Expert Summit was held in Prague, Czech Republic, from 19-20 November 2016. The meeting had a distinct advisory board character and invited aesthetic practitioners from all over the world to hear an international faculty present a range of keynote lectures and conduct live injection sessions with an emphasis on recent developments in combination aesthetic interventions for face and body rejuvenation and beautification. Aging is associated with changes in bones, muscles, ligaments, adipose tissue, and skin and, moreover, involves interactions among these tissue types...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29129441/health-related-quality-of-life-results-for-pembrolizumab-versus-chemotherapy-in-advanced-pd-l1-positive-nsclc-keynote-024-a-multicentre-international-randomised-open-label-phase-3-trial
#4
Julie R Brahmer, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Jin Zhang, Gregory M Lubiniecki, Anne C Deitz, Reshma Rangwala, Martin Reck
BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or greater (PD-L1-positive). Here we report the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-reported outcomes (PROs). METHODS: In this multicentre, international, randomised, open-label, phase 3 trial, we recruited patients with treatment-naive, stage IV NSCLC in 102 sites in 16 countries...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29117106/the-17th-rocky-mountain-virology-association-meeting
#5
Joel Rovnak, Rushika Perera, Matthew W Hopken, Jenna Read, Derrick M Waller, Randall J Cohrs
Since 2000, scientists and students from the greater Rocky Mountain region, along with invited speakers, both national and international, have gathered at the Mountain Campus of Colorado State University to discuss their area of study, present recent findings, establish or strengthen collaborations, and mentor the next generation of virologists and prionologists through formal presentations and informal discussions concerning science, grantsmanship and network development. This year, approximately 100 people attended the 17th annual Rocky Mountain Virology Association meeting, that began with a keynote presentation, and featured 29 oral and 35 poster presentations covering RNA and DNA viruses, prions, virus-host interactions and guides to successful mentorship...
November 8, 2017: Viruses
https://www.readbyqxmd.com/read/29116900/safety-and-antitumor-activity-of-the-anti-programmed-death-1-antibody-pembrolizumab-in-patients-with-advanced-esophageal-carcinoma
#6
Toshihiko Doi, Sarina A Piha-Paul, Shadia I Jalal, Sanatan Saraf, Jared Lunceford, Minori Koshiji, Jaafar Bennouna
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)-positive advanced solid tumors. Results from the esophageal carcinoma cohort are reported herein. Patients and Methods Eligible patients with squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction in whom standard therapy failed and who had PD-L1-positive tumors received pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed disease progression or intolerable toxicity...
November 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29095678/safety-and-efficacy-of-pembrolizumab-in-advanced-programmed-death-ligand-1-positive-cervical-cancer-results-from-the-phase-ib-keynote-028-trial
#7
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, Patrick A Ott, Sarina A Piha-Paul, Carlos Gomez-Roca, Emilie M J van Brummelen, Hope S Rugo, Shari Thomas, Sanatan Saraf, Reshma Rangwala, Andrea Varga
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1...
November 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29082664/keynote-speakers
#8
(no author information available yet)
No abstract text is available yet for this article.
November 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29079131/update-of-systemic-immunotherapy-for-advanced-urothelial-carcinoma
#9
REVIEW
Benjamin A Gartrell, Tianfang He, Janaki Sharma, Guru Sonpavde
PURPOSE: Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs)...
October 24, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29076757/state-of-science-ergonomics-and-global-issues
#10
Andrew Thatcher, Patrick Waterson, Andrew Todd, Neville Moray
In his 1993 IEA keynote address Neville Moray urged the ergonomics discipline to face up to the global problems facing humanity and consider how ergonomics might help find some of the solutions. In this State of Science article we critically evaluate what the ergonomics discipline has achieved in the last two and a half decades to help create a secure future for humanity. Moray's challenges for ergonomics included deriving a value structure that moves us beyond a Westernised view of worker-organisation-technology fit, taking a multidisciplinary approach which engages with other social and biological sciences, considering the gross cross-cultural factors that determine how different societies function, paying more attention to mindful consumption, and embracing the complexity of our interconnected world...
October 27, 2017: Ergonomics
https://www.readbyqxmd.com/read/29067760/hot-debate-in-hot-springs-report-on-the-second-international-meeting-on-smc-proteins
#11
Tatsuya Hirano, Tomoko Nishiyama, Katsuhiko Shirahige
The second international meeting on "SMC proteins: Chromosomal Organizers from Bacteria to Human" (SMC2017) was held in Nanyo City, Yamagata, Japan, from 13 to 16 June 2017. The meeting was attended by 134 participants (among them, 76 from outside of Japan) who were interested in one of the highly conserved classes of chromosomal proteins regulating large-scale chromosome structure and function. A keynote lecture was followed by 41 oral presentations and 71 poster presentations in the four-day meeting. Diverse topics surrounding eukaryotic SMC protein complexes (cohesins, condensins and SMC5/6) and prokaryotic SMCs, and a wide range of cutting-edge approaches (from polymer physics through medical genetics) were presented...
October 25, 2017: Genes to Cells: Devoted to Molecular & Cellular Mechanisms
https://www.readbyqxmd.com/read/29063532/transforming-data-into-knowledge-how-to-improve-the-efficiency-of-clinical-care
#12
B Séroussi, L F Soualmia, J H Holmes
Objectives: To provide an introduction to the 2017 IMIA Yearbook of Medical Informatics by the editors. Methods: We present a brief overview of the 2017 special topic "Learning from experience: Secondary use of patient data". We review our choice of special topic section editors, present the new section "Health Information Management", and discuss transitions in the editorial team. Results: In this edition of the Yearbook, we focused on one of the most important issues for the medical informatics community: The secondary use of clinical data...
August 2017: Yearbook of Medical Informatics
https://www.readbyqxmd.com/read/29061226/scientific-overview-on-csci-citac-annual-general-meeting-and-2016-young-investigators-forum
#13
Tianwei E Zhou, Kristen I Barton, Elina Cook, Matthew G K Benesch, Nicholas Jette, Christophe Moderie, Katarina Ondrusova, Caitlin Lees, Patrick E Steadman, Tina B Marvasti, Sara Mirali, Peter J Liu, Ege M Babadagli, Kara J Abraham, Kirill J Zaslavsky
The 2016 Annual General Meeting of the Canadian Society of Clinician Investigators (CSCI) and Clinician Investigator Trainee Association of Canada/Association des Cliniciens-Chercheurs en Formation du Canada (CITAC/ACCFC) was a national conference held in Toronto November 21-23, 2016, in conjunction with The University of Toronto Clinician Investigator Program Research Day. The theme for this year's meeting was "Mapping Your Career as a Clinician-Scientist"; emphasizing essential skills for developing a fruitful career as clinician-scientist...
October 19, 2017: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/29059796/keynote-plenary-speakers
#14
(no author information available yet)
Lists the Keynote or Plenary speakers and provides an abstract of the presentations with a brief professional biography of each presenter. The complete presentations were not made available for publication as part of the conference proceedings.
July 2017: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/29059432/a-phamacoeconomic-analysis-of-personalized-dosing-vs-fixed-dosing-of-pembrolizumab-in-firstline-pd-l1-positive-non-small-cell-lung-cancer
#15
Daniel A Goldstein, Noa Gordon, Michal Davidescu, Moshe Leshno, Conor E Steuer, Nikita Patel, Salomon M Stemmer, Alona Zer
Background: In October 2016, pembrolizumab became the new standard of care for firstline treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death ligand 1 in at least 50% of cells. The US Food and Drug Administration-recommended dose is 200 mg every three weeks. Multiple studies have demonstrated equivalent efficacy with weight-based doses between 2 mg/kg and 10 mg/kg. The objective of this study was to compare the economic impact of using personalized dosing (2 mg/kg) vs fixed dosing (200 mg) in the firstline setting of mNSCLC...
November 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29049091/tumor-microenvironment-and-models-of-ovarian-cancer-the-11th-biennial-rivkin-center-ovarian-cancer-research-symposium
#16
Karen McLean, Geeta Mehta
OBJECTIVE: The aim of this study was to review the latest research advances on the topics of the ovarian cancer tumor microenvironment and models of ovarian cancer. METHODS: In September 2016, a symposium of the leaders in the field of ovarian cancer research was convened to present and discuss current advances and future directions in ovarian cancer research. RESULTS: One session was dedicated to Tumor Microenvironment and Models of Ovarian Cancer, and included a keynote presentation from Anil Sood, MD, and an invited oral presentation from David Huntsman, MD...
October 18, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29040190/novel-therapeutics-for-ovarian-cancer-the-11th-biennial-rivkin-center-ovarian-cancer-research-symposium
#17
Neil Johnson, John B Liao
OBJECTIVE: The aim of this study was to summarize developments in novel therapeutics for ovarian cancer presented at the Ovarian Cancer Research Symposium held at the University of Washington. METHODS: A symposium of the leaders in ovarian cancer research was convened to present and discuss current advances and future directions in ovarian cancer research. RESULTS: The fourth session was held on September 13, 2016, and focused on Novel Therapeutics for Ovarian Cancer...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29028788/efficacy-and-safety-of-pembrolizumab-in-patients-enrolled-in-keynote-030-in-the-united-states-an-expanded-access-program
#18
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, Omid Hamid, Adil Daud, Roxana Dronca, Richard Joseph, Steven J O'Day, F S Hodi, Anna C Pavlick, Harriet Kluger, Romina P Oxborough, Aiming Yang, Mihaela Gazdoiu, Debra A Kush, Scot Ebbinghaus, April K S Salama
KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF mutant, a BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg every 3 weeks. Response was assessed by immune-related response criteria by investigator review...
November 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28987768/patient-reported-outcomes-in-keynote-006-a-randomised-study-of-pembrolizumab-versus-ipilimumab-in-patients-with-advanced-melanoma
#19
Teresa M Petrella, Caroline Robert, Erika Richtig, Wilson H Miller, Giuseppe V Masucci, Euan Walpole, Celeste Lebbe, Neil Steven, Mark R Middleton, Darcy Hille, Wei Zhou, Nageatte Ibrahim, Jonathan Cebon
OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma. PATIENTS AND METHODS: Patients received pembrolizumab 10 mg/kg every 2 (Q2W) or every 3 weeks (Q3W) for up to 2 years, or four cycles of ipilimumab 3 mg/kg Q3W. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline and throughout the study...
October 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28984207/the-international-conference-on-intelligent-biology-and-medicine-icibm-2016-summary-and-innovation-in-genomics
#20
EDITORIAL
Zhongming Zhao, Zhandong Liu, Ken Chen, Yan Guo, Genevera I Allen, Jiajie Zhang, W Jim Zheng, Jianhua Ruan
In this editorial, we first summarize the 2016 International Conference on Intelligent Biology and Medicine (ICIBM 2016) that was held on December 8-10, 2016 in Houston, Texas, USA, and then briefly introduce the ten research articles included in this supplement issue. ICIBM 2016 included four workshops or tutorials, four keynote lectures, four conference invited talks, eight concurrent scientific sessions and a poster session for 53 accepted abstracts, covering current topics in bioinformatics, systems biology, intelligent computing, and biomedical informatics...
October 3, 2017: BMC Genomics
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"